A Study To Evaluate The Effectiveness Of Spesolimab To Treat Hidradenitis Suppurativa

Overview

About this study

The purpose of this study is to assess the effectivess and safety of Spesolimab in Hidradenitis Suppurativa (HS) patients.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male or female adult patients.
  •  ≥ 18 years of age.
  • Have moderate to severe Hidradenitis Suppurativa (HS) for at least 1 year prior to the baseline visit, as determined by the investigator.
  • Have HS lesions in at least 2 distinct anatomic area.
  • Has a total abscess and inflammatory nodule (AN) count of greater than or equal to 5.
  • Total draining fistula count of less than or equal to 20.

Exclusion Criteria:

  • Individuals < 18 years of age.
  • Presence of active skin lesions other than HS that interferes with the assessment of HS.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Afsaneh Alavi, M.D.

Closed for enrollment

Contact information:

Katrina Olson

5072661078

olson.katrina@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20517830

Mayo Clinic Footer